Trade Bill

Baroness Sheehan Excerpts

2nd reading & 2nd reading (Hansard) & 2nd reading (Hansard): House of Lords
Tuesday 8th September 2020 Lords Chamber

[Baroness Sheehan (LD) [V]]

My Lords, I start by welcoming the maiden speeches of the Minister and the right reverend Prelate the Bishop of Blackburn, whose focus on inequality is very welcome. The Secretary of State for the Foreign, Commonwealth and Development Office has stated:

“With democracy and human rights as the central principle of the FCDO mission, we can bring together the UK’s values, its global mission, and its responsibilities as a world-beating international development institution.”


Those are fine words indeed, but they would have greater force if underpinned by the opportunity presented by the Bill, but that has not happened. Not only that, but Parliament’s role to set objectives, scrutinise deals and evaluate the impact on fundamentals, such as public well-being, climate requirements, human rights and international development, has been diminished. The second time around for the Trade Bill means that some of the essential safeguards won last time may be lost, given the Government’s majority. However, this House has a responsibility to uphold parliamentary sovereignty, and I will support amendments that seek to do so. To date, we have had nothing but promises from Boris Johnson to protect us from the vagaries of countries such as the US or Brazil while they are led by men whose principles and values we do not share.

I move on to the dual challenges of climate chaos and Covid-19. Some 50% of the UK’s carbon footprint appears elsewhere in the world. The Bill is an opportunity to do more to invest in green trade and use Aid for Trade support to help developing countries transition into renewables. The upcoming leadership of COP 26 gives us a real opportunity to lead on fossil fuel subsidy reform, starting with the UKEF. In 2019, the Environmental Audit Committee stated that UK Export Finance supported fossil fuel projects to the tune of £2.6 billion over the previous five years, the vast bulk of it going to low and middle-income countries, compared with just £104 million for renewable energy. It is not enough to stop subsidies for coal production. The parlous state of planetary ecosystems dictates that subsidies for oil and gas should also be consigned to history.

I end by speaking about equitable access to treatments and vaccines for Covid-19 for the developing world. Jeremy Farrar, the director of Wellcome, has said:

“For as long as COVID-19 is present somewhere, it is a threat everywhere … Governments, industry and philanthropy must pool resources to pay for the risk, the research, manufacturing and distribution.”


A recent YouGov poll commissioned by Wellcome found that most people think that Covid-19 treatments and vaccines should first be made available to those who need them the most, wherever in the world that need is greatest. Does the Minister agree, and does he agree that trade arrangements have their part to play to deliver this?

[The Deputy Speaker (Lord Duncan of Springbank) (Con)]

We will attempt to return to the noble Lord, Lord Freyberg.

Trade Bill

Baroness Sheehan Excerpts

Committee stage & Committee: 2nd sitting (Hansard) & Committee: 2nd sitting (Hansard): House of Lords
Thursday 1st October 2020 Grand Committee

Lastly, on Amendment 69, in the name of my noble friend Lady McIntosh of Pickering, I was absolutely astonished to find that one of the new conditions that my noble friend wishes to impose on a trade agreement is not lowering marketing standards for agricultural products. I really do not think that we need to protect the sizing of kiwi fruit and tomatoes; that is the least of the concerns. To set that up as an insuperable hurdle to a trade agreement is to lose all sense of proportion.

[Baroness Sheehan (LD) [V]]

My Lords, before I start, I should apologise for any noise that may interfere. There is a demonstration outside and every now and then, the volume increases.

There are a number of amendments in this group on a broad range of environmental protections. I do not intend to speak to all of them, save to say that I support them and hope that, on Report, the movers can work together to amalgamate them satisfactorily. I will, however, single out Amendment 40 which provides for the laying before Parliament of a report assessing the impact of our environmental obligations. That will be very important.

I am going to spend the rest of my time speaking to Amendment 21, to which I have added my name. In 2015, to those of us for whom climate change represents a real and looming existential threat, the Paris Agreement was received with relief. It commits Governments to submit their national plans to cut emissions and ultimately, each party to the agreement will have to do their bit to keep the rising global temperature to well below 2 degrees centigrade and to pursue efforts to limit it further, to 1.5 degrees centigrade. International agreements are initially signed to signal intent to comply but become binding only through ratification, so it is a worry when Governments do not ratify. Seven countries have not yet ratified the agreement: Turkey, Iran, Iraq, Libya, Yemen, South Sudan and Eritrea.

Turkey stands out as the only member of the G20 not to have formally endorsed the deal after Russia ratified it in October 2019. Turkey is a member of the OECD, with high economic ambitions. It has very good renewable resources and therefore the potential to reduce emissions quite significantly; and yet, it still plans massive expansion of coal-fired power stations. Turkey’s emissions increased by 135% between 1990 and 2016. This cannot go on: it really must join the rest of the G20 and signal its intent to move ahead on this agenda.

I turn to the US, which is the second largest emitter after China, accounting for 13% of global emissions. The US is still on the UN list of the original 187 countries to have ratified. However, as my noble friend Lady Northover said, it began the procedure to withdraw from the accord in 2019 and will leave on 4 November this year, I believe. President Trump remains a climate change denier. No one knows what the US elections will bring, but one thing is for sure: a Biden presidency will put the world on a much safer trajectory. Let us hope that it happens, and that it is not too late for action subsequently.

In the meantime, let us make Britain’s values and priorities clear. Action on climate change is not a “nice to have” option: it is an imperative. If, next year, we are to have a successful outcome to our presidency of COP 26 and a successful presidency of the G7, we must refuse to do business with rogue states. That sounds harsh, does it not? But if I were referring to Russia or China, one would not recoil at such a statement. The fact is that we cannot tackle climate change, halt species loss and save our oceans if we have double standards.

[The Earl of Sandwich (CB) [V]]

My Lords, as a member of the new EU International Agreements Sub-Committee, I support any attempts in this debate to improve parliamentary scrutiny, although that is not the subject of this amendment. Our committee has already examined the promising Japan FTA and much of the less promising US FTA, and we are moving on to Australia, New Zealand and, beyond that, to the Trans-Pacific Partnership Agreement. The Government have given us plenty to think about. Of course, much hangs on the overarching EU agreement, which we all await impatiently, because it affects the success of all the others.

The Minister has already acknowledged the value of our scrutiny under CRaG and that of the Commons’ IDC. I also believe that she shares my concern that CRaG is amendable and that all these FTAs and treaties should reflect the latest thinking on such issues as human rights and the SDGs, mentioned in the previous amendment.

The Minister said on Tuesday that work is being done on supply chains. It is a learning process, and I appreciate that this Bill is about continuity agreements, which already safeguard such issues. The noble Lord, Lord Lansley, has reminded us of that, and the noble Baroness, Lady Noakes, says that we are cluttering up the legislation. However, these issues are relevant because of the multitude of agreements on the horizon. Today’s amendments are about the environment and climate change, which are subjects of massive public concern.

The noble Lord, Lord Haskel, said on Tuesday that we live in different times and under rules that are mainly a consequence of our long EU membership. High environmental and technical standards are what producers, traders and investors now want and expect.

We have already heard of a range of issues that constitute possible improvements, if not to this Bill then to future agreements. I recognise how difficult it is for a Government to accommodate all the interests represented, especially as they will have to be fitted to different agreements and different countries. Formal consultation with stakeholders and the public, as well as with Parliament through explanatory memorandums, correspondence and debates, is now an accepted part of CRaG procedure, and we must celebrate that.

These amendments, alongside those on international development and the SDGs, catch my attention because they are about the planet we live on. I have spent my working life learning about conditions in other countries, and it is not difficult to agree with the conservationists and the climate changers that much more must be done to adapt the world to a more carbon-free economy. When it comes to trade, the UK has a huge advantage: it is historically a famous trading nation and is one of the foremost countries adapting to climate change and acquiring scientific and technical know-how to help other countries. Non-EU agreements must surely include proper references to international obligations, as set out in these amendments.

Last week, the Commons International Trade Committee discussed the opportunities on the environment coming up in the CPTPP—the trans-Pacific partnership agreement, of which much is expected. These include not only the Paris targets, the rules governing renewable energy, carbon reduction and transport costs, but also tighter collaboration on the handling of emergencies, such as floods and forest fires, and even an environmental tax or tariff. New Zealand’s Prime Minister is a pioneer of sustainable trade. She is also critical in the developed world’s poor response to climate change. Through the CPTPP and the UN, she will no doubt offer good advice, even to Australia, on these issues.

The mutual benefits for global trade and sustainable development in trade agreements are fast coming up the agenda. As we enter a new era of free trade, the Government would do well to pay them more than lip service. The noble Baroness, Lady Jones, is right: it is a matter of human survival.

--- Later in debate ---

[Baroness Bennett of Manor Castle (GP) [V]]

My Lords, I begin by addressing Amendment 13 in the name of the noble Lord, Lord Bassam of Brighton—ably introduced by him—to which I was pleased to attach my name. Looking at this, I cannot but think of the many wearying social media debates I engaged in about how our membership of the European Union did not stop the bringing of disastrously outsourced public services back into public hands. But that is now all history. I think all sides of the House can agree about what won the 2016 referendum. The result was a clear direction from the public on this, if not much else: take back control. That must surely apply, as a matter of priority, to public services. I look back to the 2012 Olympics, an age ago now, but it is hard to forget the G4S security fiasco, when the Army had to step in. That is what has now happened with our railways: the control that the public has long been asking for. I recall that, even in 2015, a majority of Conservative voters wanted to see our railways run for public good, not private profit. It is what should happen with the disastrously underperforming, privatised, national Covid test and trace system. The private sector can always walk away. It makes a mess and leaves the public sector to pick up the pieces. The service users suffer, the providers are loaded with debt, the public pay more and a few walk away with the profits, usually stashed in a handy tax haven.

Given the rigid ideology of the Government, I will not even ask the Minister to agree with me, but I will ask him to agree with the idea of democracy, of keeping options open, including the option to take back control of public services. It is a legal principle that one Parliament cannot bind future ones, but locking us into trade deals where a country has given its word does, presumably, have that effect under the rule of law. The amendment does not force the Government to do anything, despite the obvious public good of bringing public services back into public hands. It does prevent the closing down of democratic decision making: it keeps control. I invite the Minister to tell me why keeping our options open is a bad idea and to support Amendment 13.

The noble Baroness, Lady Thornton, has ably laid out the detail of Amendment 51, to which I was pleased to attach my name alongside those of the noble Lords, Lord Patel and Lord Fox. There is little doubt that, of all the elements of the Trade Bill, protection of the NHS has attracted the greatest attention. As many Peers have already reflected in the Committee, this is a reminder that trade Bills are of far greater public interest and concern now than they were when this House and the other place last considered them. It is a powerful path for the argument for new systems of oversight equal to those our MEPs enjoyed and the US Congress regularly utilises.

I recall taking part in a march in 2014 with the group called 999 Call for the NHS. It started in Jarrow, following in famous footsteps, although I only walked the Luton to Bedford leg. We stopped for a comfort break at an establishment along the route. A young man behind the bar asked: “Why are we suddenly so busy?” We told him: “We are marching against the privatisation of the NHS.” He said: “What? It still says NHS above the door of my doctor’s surgery.”

Of course we know that that is not true: there is significant privatisation already. To cite just one statistic, 13% of in-patient mental healthcare beds in England are privately run. In Manchester, patients have a 50:50 chance of being admitted to a privately owned hospital and a one in four chance of the bed being provided by an American-owned company. We have lost control in significant areas of the NHS. This amendment makes sure that we can take it back and not lose further control.

Finally, I will refer briefly to Amendment 75. We have yet to hear from the noble Baroness, Lady Sheehan, and I look forward to her explanation, but my eye notes with approval the amendment’s provision against the use of investor-state dispute settlement procedures—another great threat to public democratic control and decision-making and something that the Green Party has long campaigned against. Protection of access to generic affordable drugs and preventing excess windfall profits for pharmaceutical companies: I cannot see anything not to like in this amendment.

[Baroness Sheehan (LD) [V]]

My Lords, I will speak to Amendment 75 in my name. Intellectual property rights, if governed badly, can result in monopolies and unethical practices, particularly when it comes to pharmaceutical companies and medicines. In recent years, these practices have become more commonplace. Indeed, the NHS’s spiralling drugs bill led even the Health Secretary, Matt Hancock, to recognise that pharmaceutical companies are trying to, in his words, “rip off taxpayers”, and that big business must be more socially responsible. Something must be terribly wrong. In an interview in the Times, he condemns profiteering on products that rely on government-funded research and NHS patient data.

In the UK, high prices have put pressure on national health budgets and led to the rationing of treatments—for example, on breakthrough medicines for hepatitis C and cancer. There are also significant delays for cystic fibrosis patients to get access to the drug Orkambi given the unaffordable price that the pharmaceutical company Vertex was demanding. It took years of stalled negotiations between NICE and Vertex and the threat of a compulsory licence to push Vertex to lower the price. In the meantime, 200 people died. The breast cancer drug trastuzumab—I hope I said that correctly—is unavailable to the vast majority of women across the developing world because Roche holds multiple patents on the drug in South Africa, blocking biosimilars from being sold in the country until 2033. This is despite the fact that trastuzumab is included in the WHO’s essential medicines list.

These and other examples of unethical pricing regimes by pharmaceutical companies prompted me to put forward my Amendment 75. It aims to ensure that a Government’s right to use internationally agreed safeguards—such as they are in medicines—to protect public health, with a particular focus on securing access to less costly generic medicines, is not undermined or restricted by international trade agreements to which we are a party.

The amendment is rooted in the UN’s International Covenant on Economic, Social and Cultural Rights 1966, which is a binding international human rights treaty that we in the UK ratified in 1976. The ICESCR ensures the enjoyment of economic, social and cultural rights, including—and this is the part that is pertinent to the amendment—the right to the highest attainable standard of health. What Government would not aspire to the best available healthcare for their citizens? But whether they would want that or not is immaterial; if they are a party to the ICESCR then this is a statutory duty that they owe their citizens. That is the point of the amendment. It puts on the face of the Bill something that is not just nice to have but that the Government are already committed to and should be proud of: to proclaim their commitment to the highest standard of health for all their citizens.

Trade Bill

Baroness Sheehan Excerpts

Committee stage & Committee: 4th sitting (Hansard) & Committee: 4th sitting (Hansard): House of Lords
Thursday 8th October 2020 Grand Committee

[The Deputy Chairman of Committees (Lord McNicol of West Kilbride) (Lab)]

We are trying to contact the noble Lord, Lord McConnell, but we have not been able to reach him and are checking to see whether that is due to technical failure. I therefore call the noble Baroness, Lady Sheehan.

[Baroness Sheehan (LD) [V]]

My Lords, it is a pleasure to follow my noble friend Lord Purvis of Tweed, whose grasp of the particular issues that developing countries face is well grounded through his leading role in the All-Party Group on Trade Out of Poverty, which he mentioned at the start, and which complements his demonstrated knowledge of trade matters in general. I thought I would be following the noble Lord, Lord McConnell of Glenscorrodale, so I will leave out a bit of my speech.

Amendment 39, to which I have added my name, seeks to ensure that trade agreements take full heed of the UN SDGs, or sustainable development goals, which the UK in no small measure helped to craft, along with an impact assessment report back to Parliament on progress towards meeting those SDGs. Embedding the SDGs in our trading ethos, which Amendment 39 seeks to do, will go beyond mere words and take ownership of a much-lauded initiative that we were instrumental in delivering, defining our determination to establish Britain as a force for good in the world, which is after all the stated aim of Dominic Raab, the Secretary of State of the newly created FCDO. I am concerned to hear about the cutting of the ODA specifically to implement trade agreements with developing countries. That is very disappointing, and I look forward to hearing the Minister’s response on that.

If we were to embed the SDGs into the new trade agreements, we would be keeping in step with the WTO, which has embraced the ambition of the SDGs and recognises its own central role in delivering them. The WTO’s publication Mainstreaming Trade to Attain the Sustainable Development Goals shows its commitment to delivering and implementing pro-growth and pro-development trade reforms, and which are crucial to prosperity for us here in the UK as well as for the rest of the world. Without a fair trading scheme, we will not realise the ambitions to protect our planet as we make good social injustices, and that is the purpose behind Amendment 97 in the name of my noble friend Lord Purvis of Tweed, with the welcome support of the noble Baroness, Lady Bennett of Manor Castle.

Least developed countries and low and middle-income countries have a few privileges when it comes to trade with more developed countries without which they would never get off the starting block in the cut-throat world of international trade. I urge the Minister to do all he can to expedite the rollover agreements with developing countries we have through the EU which to date have not been the subject of continuity agreements. The sooner that happens, the better. I think my noble friend Lord Purvis pointed to the east African states and Kenya where that has yet to take place.

The existing concessions for market access for developing countries, such as Everything But Arms and preference schemes, must continue and they need to be guaranteed as we carve out new deals post Brexit. I say that advisedly. The Minister repeatedly insists that this Bill has a limited remit to apply only to continuity agreements, but that is not what is written in the Bill. The Long Title starts:

“A BILL TO Make provision about the implementation of international trade agreements”.


There is no mention of continuity agreements. It is therefore little wonder that so many amendments have been tabled to secure in the Bill safeguards for existing standards that our citizens hold dear in so many spheres of their lives. Britain’s reputation for thorough, open and regular scrutiny, something that the noble Baroness, Lady Fairhead, remarked upon repeatedly, is in no small measure the backbone of our good standing on the international stage and should not be given up.

Amendment 97 would impose a duty on the Government of the day to lay a report before Parliament on a regular basis assessing the economic and developmental impact of each free trade deal between Britain and least developed and lower middle income countries. This is a powerful requirement, the mere knowledge of which will act as a positive incentive to the Government of the day to keep in place existing measures to deliver the “gold standard”, as the Fairtrade Foundation puts it, in the trade for development policy. That is what we are looking for: a gold standard in trade for development policy. It will go a long way toward securing—I again quote the Fairtrade Foundation,

“an overarching trade strategy that works in support of the SDGs, business and human rights and climate change commitments.”

I shall end my contribution with a few words on fossil fuel subsidies and their abundant use in our trading relationships with developing countries. If you believe, as I do, that unless we stop climate change, we will destroy life as we know it on our plant, we must stop burning fossil fuels. It makes little sense to me that we, through UK Export Finance, continue to subsidise investment in new fossil fuel infrastructure in developing countries as if existing infrastructure will not take us over the two degrees of warming that spells disaster. The argument is often put forward that not to help former colonies to harness energy from oil or gas somehow harks back to colonial times when Britain dictated economics abroad. That is pure bunkum. It is far more reminiscent of the colonial era to lock former colonies into soon-to-be defunct stranded assets and pocket the profits at the same time as we in the west equip ourselves with modern, clean and cheaper energy infrastructure. My plea to the Government is that they stop subsiding fossil fuel infrastructure here and abroad and transfer those subsidies to clean renewables, such as solar, wind and hydro, which present plenty of opportunities to do business in developing countries.

Trade Bill

Baroness Sheehan Excerpts

Report stage & Report stage (Hansard): House of Lords & Report: 1st sitting & Report: 1st sitting: House of Lords
Monday 7th December 2020 Lords Chamber

[Lord Freyberg (CB)]

My Lords, I am delighted to follow the noble Baroness, Lady Thornton, and congratulate her on her excellent and persuasive speech. I am pleased to contribute to consideration on Report of the Trade Bill and to speak to the new Amendment 11.

There is some question as to the status of new and enhanced digital trade provisions in replacement deals, such as the CEPA signed by the UK and Japan in September, and those promised next year in relation to the UK’s CETA with Canada, which are said to expand pre-existing agreements. These provisions have implications for health and care in the UK and warrant further discussion, despite the advice note issued by the Minister’s department on Friday—hence my decision to press the issues which I raised in Committee.

Amendment 11 would safeguard state control of policy-making and the use of publicly funded health and care data. This capability is of vital importance in the context of the pandemic, but it should be guaranteed in perpetuity, since it underpins the efficient and effective operation of publicly funded health and care services in the UK, as well as those data-driven health services managed at present by, for example, Public Health England and the Joint Biosecurity Centre. It also amounts to a significant national asset or resource with the potential to function as a dynamo in relation to research, innovation and continued growth of the UK’s life sciences, health and care tech sectors. The Trade Bill should recognise this and incorporate explicit provisions preventing the outsourcing of digital infrastructure that is critical to the nation’s health and wealth and, by implication, the loss of skilled personnel working in data analytics to support core health and care functions alongside research and development activity.

Agreement to Amendment 11 would also safeguard the state’s ability to regulate and maintain the level of protection afforded to health and care data relating to UK citizens. The Government seek to champion the free flow of data; this is writ large in the CEPA as well as in their recently issued advice notes on the subject. I am also mindful that the CEPA does not in itself change UK data protection laws. However, the Government should consider how the Trade Bill and enhanced provisions in rollover trade agreements could contribute to, or detract from, the public’s perception of their trustworthiness and accountability in relation to health and care data usage by third parties. After all, informed consent is the foundation on which UK GDPR is based.

The Government have stated that the CEPA deal

“removes unjustified barriers to data flows to ensure UK companies can access the Japanese market and provide digital services. It does this by limiting the ability for governments to put in place unjustified rules that prevent data from flowing and create barriers to trade.”

Does the Minister consider restrictions on the free flow of, for example, genomic and biometric data about citizens justifiable or not? Would he not, for example, consider it helpful to commit to data localisation or minimum cybersecurity standards to safeguard certain types of sensitive personal data? Having entered into the CEPA with Japan, are the Government now unable to insist on such rules? In putting my name to this amendment, I am concerned to ensure that the Government have not already tied the hands of policymakers and regulators, including the Information Commissioner.

Agreement to subsection (3)(c) in the proposed new clause inserted by Amendment 11 would prevent the introduction of any ISDS clause regarding data access and processing in relation to health data to a rollover or enhanced trade agreement. The Government continue to invest significant funds in research and development and are committed to leveraging private investment to propel the UK’s R&D effort. I feel sure—in fact, I will wager—that securing foreign direct investment in health and care data will be a feature of their trade negotiation strategy. However, in the interests of guaranteeing value for taxpayers’ money, the Government should not find themselves in a position where they are at risk of legal action from their trading partners or multinationals if, for example, they want to offer discounted access to health and care data assets for UK SMEs to stimulate homegrown economic development or invest to create employment opportunities in deprived communities in relation to the clean-up or curation of health and care data.

The Minister remarked in an earlier reply to me that ISDS provisions do not feature in the rollover trade agreements with which this Bill is primarily concerned. I also think I am right in saying that, rather than opting for ISDS in negotiating the CEPA, the Government agreed with Japan that the agreement would be subject to the World Trade Organization’s Dispute Settlement Body. That is not to say that other rollover agreements still to be finalised will not incorporate reference to ISDS, and nor do I profess a preference for reliance on the WTO’s dispute settlement body vis-à-vis claims that might arise in relation to government decisions on health and care data, since the UK will pose a less significant risk to those claimants who may be backed by big tech once separated from the European Union in earnest. I therefore stand by the amendment, which would prevent such claims arising in the first place.

Agreement to subsection (3)(f) of Amendment 11 reads across to a topic that I have spoken about on many occasions in this place: namely, the value of healthcare data. There is widespread recognition that the NHS uniquely controls nationwide longitudinal healthcare data, which has the potential to generate clinical, social and economic development as well as commercial value. The Government should take steps to protect and harness the value of that data and, in the context of the Trade Bill, ensure that the public can be satisfied that that value will be safeguarded and, where appropriate, ring-fenced and reinvested in the UK’s health and care system. The Government have stated that the UK-Japan deal includes agreement to encourage

“the release of anonymised government datasets where appropriate”

because public access to government datasets creates opportunities for innovative British businesses. Once again, the trade deal cuts both ways; I do not believe that the general public support a “great health data giveaway” of benefit to companies headquartered and paying taxes overseas.

Finally, conscious of time, I encourage the Minister to reflect upon my contribution to the discussion of the Medicines and Medical Devices Bill in Committee, and the helpful response of the noble Baroness, Lady Penn, which confirmed that the Government mean to undertake a review of pertinent regulations over the coming year, including the definition of a medical device and the regulation of algorithms and artificial intelligence in pertinent tools and innovations. I am concerned that the effect of provisions in some trade agreements could be to reduce access to the algorithms that underpin them.

None can doubt the need to prioritise the safety of the public as new treatments and technologies are developed in the face of the Covid-19 pandemic and traded under both existing and new agreements that the Government might enter into with other countries. Yet, according to the Government’s advice note published on 4 November, the CEPA entered into by the UK and Japan will prevent the forced transfer of algorithms. The Trade Bill should contain up-to-date provisions to guarantee patient safety against this backdrop because it is unclear whether Article 8.3 of the CEPA—which provides a general exemption for measures deemed necessary to protect human health—would override provisions concerning the forced transfer of algorithms. Agreement to subsection (4) of Amendment 11 would have that effect.

I am passionate about harnessing the value of health and care data that is generated by, with and about UK citizens. The Government should, however, take note of those protections to which I have put my name in supporting Amendment 11; these are designed to maintain public confidence in our brave, new, data-driven world.

[Baroness Sheehan (LD) [V]]

My Lords, Amendment 43 in my name provides for safeguards to trade agreements to ensure affordable access to medicines for all. I thank my noble friend Lord Purvis of Tweed and the noble Lord, Lord Alton, for adding their names. I express my support for Amendment 11 in the names of the noble Baroness, Lady Thornton, the noble Lords, Lord Freyberg and Lord Patel, and my noble friend Lord Fox. It dovetails nicely with my Amendment 43 in seeking to protect the NHS and connected services from control through free trade agreements; Amendment 43 seeks to affirm fair access to affordable medicines for international agreements to which the UK is already a party.

The monopoly system created by the pharmaceutical business model is entrenched globally through the WTO’s 1995 TRIPS agreement—the Agreement on Trade-Related Aspects of International Property Rights. Included within it are provisions to safeguard public health. However, concerns about affordable medicines in developing countries, particularly access to antiretroviral drugs in the face of the HIV/AIDS epidemic, led to the Doha declaration in 2001. These identified options open for Governments to address public health needs, which are known as flexibilities. The importance of such flexibilities was highlighted by their inclusion in the UN’s sustainable development goals.

However, despite these safeguards, the misuse and abuse of these monopoly rights continue and are taking precedence over human rights in all countries of the world, not just developing ones. The NHS’s spiralling drugs bill led even the Health Secretary, Matt Hancock, to protest that pharmaceutical companies are “ripping off taxpayers”. I have no objection to profit-making by companies, but I object vehemently to people suffering and dying needlessly under the NHS because of quite obscene profit-taking by pharmaceutical companies, as happened with Vertex’s cystic fibrosis drug Orkambi. In South Africa, private health companies are charging $39,000—an obscene amount—for Trastuzumab, a WHO essential drug to treat breast cancer. This is a human rights issue.

Trade Bill

Baroness Sheehan Excerpts

Report stage & Report: 2nd sitting (Hansard) & Report: 2nd sitting (Hansard): House of Lords
Tuesday 15th December 2020 Lords Chamber

[Baroness Noakes (Con)]

My Lords, I shall focus my very brief remarks on Amendment 16 in this group—mainly because, when I saw Amendment 25, I had no idea what it was about. I have now heard what the noble Lord has said and I am sure that my noble friend the Minister will respond in due course. When I looked at Amendment 16, I really could not see what kind of problem it was trying to solve; not only is it unnecessary for a statute to repeat commitments that have been made but the environment for aid is now governed by the 2002 Act, which is pretty clear about where aid can and cannot be given.

The noble Lord, Lord Purvis of Tweed, may have concerns about what the Foreign Secretary may or may not have said, but for something to change the law may have to change and the noble Lord would have plenty of opportunity to engage with that issue as and when such a change was made. The noble Lord was good enough to say that the UK has an extremely good record on tied aid and has had so for a very long time; this is not a new commitment needing to be made. I repeat what I always say: it is unnecessary to put in legislation things that noble Lords are worried about—things that might be changed in the future or commitments that might not be kept up. However, if the noble Lord is merely tabling a probing amendment, looking for my noble friend the Minister to reiterate where the Government currently stand on tied aid, obviously there is no real issue. Apart from that, I just say to the noble Lord that the amendment is pretty unnecessary.

[Baroness Sheehan (LD) [V]]

My Lords, I will say a few short words about Amendment 16, which may enlighten the noble Baroness, Lady Noakes, as to why I think it is very important. I am grateful to my noble friend Lord Purvis of Tweed for putting it down.

The Pergau dam scandal of the early 1990s offers a timely reminder of how badly things can go wrong when tied aid becomes, as it did then, a regular feature of the aid budget—so much so that, in 1997, the UK’s aid budget was removed from the Foreign Secretary’s remit and placed with a newly formed Department for International Development. Maybe old habits die hard as this was followed in fairly short order by the International Development Act 2002, which tightly defined development assistance as two things: furthering sustainable development and improving the welfare of people in developing countries. It was designed to be pro-poor and, in effect, to ensure no more tied aid.

However, that and other Acts of Parliament on international development now have a sword of Damocles hanging over them. My noble friend Lord Purvis has outlined in quite a lot of detail the conflicting statements that we have heard with respect to the 0.7% target, which, as we now know, is to be reduced to 0.5%. He has therefore quite sensibly covered every eventuality in his Amendment 16 by invoking the OECD Development Assistance Committee’s recommendation on untying official development assistance. I hope the Minister will add his assurances to those of the Foreign Secretary and tell us that the bad old days of tied aid are indeed over. Trust is a hard-won commodity, and it is running in very short supply with this Government. I ask the Minister, whose word I have no reason to mistrust, to ensure that assurances given at the Dispatch Box are followed through.

Turning to Amendment 25, to which I have added my name, the Government’s early commitments post Brexit to protect current trading relationships with poorer countries, keep prices in check and help build our future trading partners are not turning out to be quite as reliable as we would have hoped, as with many other government commitments post Brexit. It now looks as though the world’s poorest countries will instead face additional challenges post Brexit. Quite a lot are being overcome, but not all.

Amendment 25 is necessary to ensure that developing countries do not lose market access or share, either because time has run out to agree continuity deals or because other arrangements have run into difficulties. Including some of those countries which could face higher tariffs in the list of least developed countries, as per proposed new subsection (2), would offer some protection.

My noble friend Lord Purvis has explained some of the issues surrounding our difficulties in agreeing a trading arrangement with Ghana. I hope the Minister will agree that insisting on a historic stepping-stone deal was unrealistic. As my noble friend said, Ghana asked that the existing ECOWAS EPA with the EU be used as a basis; I am delighted to learn from my noble friend that it will form the basis of ongoing negotiations. To have insisted that the stepping-stone agreement should form the basis of agreements going forward with Ghana was to disregard the fact that it is now a member of ECOWAS—the Economic Community of West African States—and as such has notified that agreement under the WTO. That would break international agreements, which I hope the Minister would agree is not a good look.

Ghana could have signed our agreement for the enhanced framework as a way out of the scheme but, as my noble friend Lord Purvis explained, it was presented with some difficulties in doing so because bananas are not included in the enhanced framework scheme. I hope this issue can be resolved so that other countries are not caught in the same trap. Had Ghana signed up to the enhanced framework scheme, about 30% of the bananas we eat in the UK, which come from Ghana, could not have got here. That would be a real shame, because a large proportion of them are Fairtrade; the Fairtrade Foundation has had great success in getting better working conditions and fairer deals for poorer farmers and the workers and communities that rely on them. I do not need to remind the Minister that the Fairtrade movement enjoys wide support in the UK. Proposed new subsection (3) is designed to overcome this difficulty for Ghana and other developing countries caught in a similar conundrum.

Time is tight, so I will move straight to the end. The regional economic unions in Africa—east, south, north and west—are now all pretty well established and the African Continental Free Trade Area, which represents a market of 1.2 billion people with a combined GDP of $1.3 trillion, opens on 1 January 2021. This October, just a few weeks ago, talks took place between the EU and the African Union on a modern relationship between the two trading blocs. What plans do we have for a modern trading arrangement with the African Union?

[Baroness McIntosh of Pickering (Con)]

My Lords, in connection to Amendments 16 and 25, I really would prefer to go down the continuity agreement route than to adopt these two. It is my understanding that the UK has reached—I think the noble Lord, Lord Purvis, said this in moving Amendment 16—a rollover agreement with Kenya. Indeed, it was signed this month, less than a week ago, which I welcome. I know that we had a long debate in Committee about the asymmetry of many of the free trade agreements, but I do not know if that applies in this case. It would be my strong preference that we press the Government to continue their good work in reaching agreements, with the rollover economic partnership free trade agreements.

My question to the Minister is therefore very simple: could he say where we are in reaching agreement with Ghana—which reached an EPA with the EU relatively recently, in 2016—and Cameroon, which reached an EPA with the EU in 2014? Rather than at this stage lumbering the Government with even more add-ons, as set out in Amendments 16 and 25, it would be my preference to carry on the work that they have achieved with the Kenya rollover agreement. I urge my noble friend the Minister to continue to complete the agreements with Ghana and Cameroon.

My noble friend said earlier—it was not his exact phrase—that it takes two to tango. It takes two to complete these agreements, and if any specific obstacles have been raised with any specific products relating to the rollover agreements we currently enjoy, through our membership of the EU, with Ghana and Cameroon, it would be very helpful to know what they are this afternoon.